# AARDVARK THERAPEUTICS, INC. (AARD) · Edgar & Edgarette company card

> Aardvark Therapeutics (AARD) reported revenue of $0 million in FY2025, operating margin null against a -3.8% median for pharmaceutical preparations, equity 91.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1774857 · fiscal year ended 2025-12-31 · 1 audited years read · [page](https://www.pops4.com/boards/company/AARD) · [JSON](https://www.pops4.com/boards/company/AARD.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% |
| Net margin | -Infinity% |
| Operating cash flow | −$54M |
| Capital spending | $95,000 |
| Free cash flow | −$54M |
| Cash | $47M |
| Long-term debt | — |
| Total assets | $117M |
| Total equity | $107M |
| Equity ÷ assets | 91.0% |
| Return on equity | -54.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 9.47 (safe zone)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$54.2M in FY2025); operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: one year on record; operating margin null. Soundness: equity 91.0% of assets, return on equity -54.0%. Credibility: one audited year, little weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-10-08 ([filing](https://www.sec.gov/Archives/edgar/data/1774857/000119312526417935/0001193125-26-417935-index.htm))

## Recent filings

- 8-K · filed 2026-11-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1774857/000119312526459373/0001193125-26-459373-index.htm)
- 10-Q · filed 2026-11-13 · [filing](https://www.sec.gov/Archives/edgar/data/1774857/000119312526458957/0001193125-26-458957-index.htm)
- 8-K · filed 2026-10-23 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1774857/000119312526429509/0001193125-26-429509-index.htm)
- 8-K · filed 2026-10-22 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1774857/000119312526428943/0001193125-26-428943-index.htm)
- 8-K · filed 2026-10-08 · 5.02 Departure or Election of Directors; Appointment of Officers; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1774857/000119312526417935/0001193125-26-417935-index.htm)
- 8-K · filed 2026-08-17 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1774857/000119312526354053/0001193125-26-354053-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001774857.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1774857

## Cite

POPS4, Edgar & Edgarette: AARDVARK THERAPEUTICS, INC. (AARD) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/AARD. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

